Showing results (61-70 of 68) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Cancer Immunology, Immunotherapy : CII|October 24, 2000
Synergy between interleukin-2 and prothymosin alpha for the increased generation of cytotoxic T lymphocytes against autologous human carcinomasI F Voutsas, C N Baxevanis, A D Gritzapis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1992
The prognostic significance of immune changes in patients with renal cell carcinoma treated with interferon alfa-2bP A Kosmidis, C N Baxevanis, N Tsavaris, et al.Anticancer Research|March 1, 1992
Monocyte disorders associated with T cell defects in patients with solid tumorsE Anastasopoulos, G J Reclos, C N Baxevanis, et al.Natural Immunity|January 1, 1993
Comparison of immune parameters in patients with one or two primary malignant neoplasmsC N Baxevanis, G J Reclos, A D Gritzapis, et al.Immunopharmacology and Immunotoxicology|September 15, 1998
Mistletoe lectin I-induced effects on human cytotoxic lymphocytes. I. Synergism with IL-2 in the induction of enhanced LAK cytotoxicityC N Baxevanis, I F Voutsas, M H Soler, et al.British Journal of Cancer|November 27, 2001
Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitopeR Sotiriadou, S A Perez, A D Gritzapis, et al.Anticancer Research|July 23, 1998
The prognostic value of alpha-thymosins in breast cancerO E Tsitsilonis, E Bekris, I F Voutsas, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrenceE A Mittendorf, A Ardavanis, J Symanowski, et al.Pageof 7